N/A
Completed N=200
Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department
Influenza, Human
Source: ClinicalTrials.gov NCT02899065 ↗
Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcomePrimary: Number of Participants Prescribed Antibiotics — 39; 32 Participants
Summary
This will be a prospective, patient-oriented, pilot randomized clinical trial to evaluate (in aggregate) both the use of the Roche Cobas Liat Flu/RSV Assay and the use of pharmacist-led education for providers in the interpretation of these test results.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Prescribed Antibiotics |
39; 32 | — |
| PRIMARY Number of Participants Prescribed Antiviral Therapy |
12; 10 | — |
| SECONDARY Emergency Department Recidivism |
19; 16 | — |
| SECONDARY Symptom Resolution |
66; 52; 62; 61 | — |
| SECONDARY Lost Days of School/Work |
2.6; 2.6; 2.5; 3.1; 1.8; 1.4 | — |
Eligibility Criteria
Inclusion Criteria
- Patients 38 degrees Celsius and cough or sore throat), or
- non-specific upper respiratory infection (URI) for whom the clinician suspects the presence of RSV, or influenza, or lower respiratory infection LRI).
- Patients whose treating provider has ordered a Roche Cobas Liat Flu/RSV test.
Exclusion Criteria
- Patients who are pregnant
- Prisoners
- Patients who are unable to give informed consent in English or Spanish.
- Provider is unwilling to wait for procalcitonin results.
Data sourced from ClinicalTrials.gov (NCT02899065). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.